Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation

Ciro Costagliola, Mario R. Romano, Roberto dell'Omo, Ugo Cipollone, Paolo Polisena

Research output: Contribution to journalArticle

Abstract

Purpose: To verify the potential efficacy of intravitreal bevacizumab (IVB) injections for the treatment of retinal angiomatous proliferation (RAP). Design: Retrospective interventional case series. Methods: Four consecutive patients affected by RAP at different stages and refractory to photodynamic therapy (PDT). All patients underwent a complete ophthalmic examination including best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographies, and optical coherence tomography (OCT) at baseline, and after one, three, six, nine, and 12 months. All patients received IVB injections (1.25 mg/0.05 ml). Results: The best functional response has been achieved in patients with RAP at stages 1 and 2; whereas in stage 3, a detectable recovery of visual acuity was not observed. This improvement was stable over the follow-up period with a concomitant reduction of macular thickness. Conclusions: The use of IVB in patients affected by RAP seems to exert morphologic benefits at all RAP stages that does not always correspond a functional improvement.

Original languageEnglish
Pages (from-to)449-451
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume144
Issue number3
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Intravitreal Injections
Visual Acuity
Therapeutics
Indocyanine Green
Photochemotherapy
Optical Coherence Tomography
Fluorescein
Angiography
Bevacizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Costagliola, C., Romano, M. R., dell'Omo, R., Cipollone, U., & Polisena, P. (2007). Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 144(3), 449-451. https://doi.org/10.1016/j.ajo.2007.05.025

Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation. / Costagliola, Ciro; Romano, Mario R.; dell'Omo, Roberto; Cipollone, Ugo; Polisena, Paolo.

In: American Journal of Ophthalmology, Vol. 144, No. 3, 09.2007, p. 449-451.

Research output: Contribution to journalArticle

Costagliola, C, Romano, MR, dell'Omo, R, Cipollone, U & Polisena, P 2007, 'Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation', American Journal of Ophthalmology, vol. 144, no. 3, pp. 449-451. https://doi.org/10.1016/j.ajo.2007.05.025
Costagliola, Ciro ; Romano, Mario R. ; dell'Omo, Roberto ; Cipollone, Ugo ; Polisena, Paolo. / Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation. In: American Journal of Ophthalmology. 2007 ; Vol. 144, No. 3. pp. 449-451.
@article{f0f90fbdba224d5b96c5d1cd30e925b7,
title = "Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation",
abstract = "Purpose: To verify the potential efficacy of intravitreal bevacizumab (IVB) injections for the treatment of retinal angiomatous proliferation (RAP). Design: Retrospective interventional case series. Methods: Four consecutive patients affected by RAP at different stages and refractory to photodynamic therapy (PDT). All patients underwent a complete ophthalmic examination including best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographies, and optical coherence tomography (OCT) at baseline, and after one, three, six, nine, and 12 months. All patients received IVB injections (1.25 mg/0.05 ml). Results: The best functional response has been achieved in patients with RAP at stages 1 and 2; whereas in stage 3, a detectable recovery of visual acuity was not observed. This improvement was stable over the follow-up period with a concomitant reduction of macular thickness. Conclusions: The use of IVB in patients affected by RAP seems to exert morphologic benefits at all RAP stages that does not always correspond a functional improvement.",
author = "Ciro Costagliola and Romano, {Mario R.} and Roberto dell'Omo and Ugo Cipollone and Paolo Polisena",
year = "2007",
month = "9",
doi = "10.1016/j.ajo.2007.05.025",
language = "English",
volume = "144",
pages = "449--451",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation

AU - Costagliola, Ciro

AU - Romano, Mario R.

AU - dell'Omo, Roberto

AU - Cipollone, Ugo

AU - Polisena, Paolo

PY - 2007/9

Y1 - 2007/9

N2 - Purpose: To verify the potential efficacy of intravitreal bevacizumab (IVB) injections for the treatment of retinal angiomatous proliferation (RAP). Design: Retrospective interventional case series. Methods: Four consecutive patients affected by RAP at different stages and refractory to photodynamic therapy (PDT). All patients underwent a complete ophthalmic examination including best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographies, and optical coherence tomography (OCT) at baseline, and after one, three, six, nine, and 12 months. All patients received IVB injections (1.25 mg/0.05 ml). Results: The best functional response has been achieved in patients with RAP at stages 1 and 2; whereas in stage 3, a detectable recovery of visual acuity was not observed. This improvement was stable over the follow-up period with a concomitant reduction of macular thickness. Conclusions: The use of IVB in patients affected by RAP seems to exert morphologic benefits at all RAP stages that does not always correspond a functional improvement.

AB - Purpose: To verify the potential efficacy of intravitreal bevacizumab (IVB) injections for the treatment of retinal angiomatous proliferation (RAP). Design: Retrospective interventional case series. Methods: Four consecutive patients affected by RAP at different stages and refractory to photodynamic therapy (PDT). All patients underwent a complete ophthalmic examination including best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographies, and optical coherence tomography (OCT) at baseline, and after one, three, six, nine, and 12 months. All patients received IVB injections (1.25 mg/0.05 ml). Results: The best functional response has been achieved in patients with RAP at stages 1 and 2; whereas in stage 3, a detectable recovery of visual acuity was not observed. This improvement was stable over the follow-up period with a concomitant reduction of macular thickness. Conclusions: The use of IVB in patients affected by RAP seems to exert morphologic benefits at all RAP stages that does not always correspond a functional improvement.

UR - http://www.scopus.com/inward/record.url?scp=34548329843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548329843&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2007.05.025

DO - 10.1016/j.ajo.2007.05.025

M3 - Article

C2 - 17765426

AN - SCOPUS:34548329843

VL - 144

SP - 449

EP - 451

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -